{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:19:06Z","timestamp":1787505546786,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institutes of Health under National Cancer Institute","award":["1U01CA199218"],"award-info":[{"award-number":["1U01CA199218"]}]},{"name":"National Institutes of Health under National Cancer Institute","award":["R01CA164301"],"award-info":[{"award-number":["R01CA164301"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The incidence of ductal carcinoma in situ (DCIS) has increased substantially since the introduction of mammography screening. Nevertheless, little is known about the natural history of preclinical DCIS in the absence of biopsy or complete excision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two well-established population models evaluated six possible DCIS natural history submodels. The submodels assumed 30%, 50%, or 80% of breast lesions progress from undetectable DCIS to preclinical screen-detectable DCIS; each model additionally allowed or prohibited DCIS regression. Preclinical screen-detectable DCIS could also progress to clinical DCIS or invasive breast cancer (IBC). Applying US population screening dissemination patterns, the models projected age-specific DCIS and IBC incidence that were compared to Surveillance, Epidemiology, and End Results data. Models estimated mean sojourn time (MST) in the preclinical screen-detectable DCIS state, overdiagnosis, and the risk of progression from preclinical screen-detectable DCIS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Without biopsy and surgical excision, the majority of DCIS (64\u2013100%) in the preclinical screen-detectable state progressed to IBC in submodels assuming no DCIS regression (36\u2013100% in submodels allowing for DCIS regression). DCIS overdiagnosis differed substantially between models and submodels, 3.1\u201365.8%. IBC overdiagnosis ranged 1.3\u20132.4%. Submodels assuming DCIS regression resulted in a higher DCIS overdiagnosis than submodels without DCIS regression. MST for progressive DCIS varied between 0.2 and 2.5\u2009years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that the majority of screen-detectable but unbiopsied preclinical DCIS lesions progress to IBC and that the MST is relatively short. Nevertheless, due to the heterogeneity of DCIS, more research is needed to understand the progression of DCIS by grades and molecular subtypes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-020-01287-6","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T05:02:48Z","timestamp":1590555768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Modeling the natural history of ductal carcinoma in situ based on population data"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7714-4737","authenticated-orcid":false,"given":"Sarocha","family":"Chootipongchaivat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolien T.","family":"van Ravesteyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Weedon-Fekj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc D.","family":"Ryser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S.","family":"Burnside","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandy M.","family":"Heckman-Stoddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry J.","family":"de Koning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"issue":"6","key":"1287_CR1","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.jamcollsurg.2019.01.018","volume":"228","author":"B Zhang","year":"2019","unstructured":"Oseni TO, Zhang B, Coopey SB, Gadd MA, Hughes KS, Chang DC. Twenty-five year trends in the incidence of ductal carcinoma in situ in US women. J Am Coll Surg. 2019;228(6):932\u20139.","journal-title":"J Am Coll Surg"},{"issue":"2","key":"1287_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/bcr1397","volume":"8","author":"JL Jones","year":"2006","unstructured":"Jones JL. Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in situ: the pathological perspective. Breast Cancer Res. 2006;8(2):204.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"1287_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ejso.2017.12.007","volume":"44","author":"AJ Maxwell","year":"2018","unstructured":"Maxwell AJ, Clements MK, Hilton MB, Dodwell DJ, Evans A, Kearins MO, et al. Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. Eur J Surg Oncol. 2018;44(4):429\u201335.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"1287_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-005-9101-z","volume":"97","author":"B Erbas","year":"2006","unstructured":"Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97(2):135\u201344.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1287_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3322\/canjclin.52.5.256","volume":"52","author":"M Morrow","year":"2002","unstructured":"Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble B, Harris JR, et al. Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin. 2002;52(5):256\u201376.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1287_CR6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y","volume":"49","author":"DL Page","year":"1982","unstructured":"Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer. 1982;49(4):751\u20138.","journal-title":"Cancer."},{"issue":"12","key":"1287_CR7","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1002\/cncr.21069","volume":"103","author":"ME Sanders","year":"2005","unstructured":"Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005;103(12):2481\u20134.","journal-title":"Cancer."},{"issue":"5","key":"1287_CR8","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/modpathol.2014.141","volume":"28","author":"ME Sanders","year":"2015","unstructured":"Sanders ME, Schuyler PA, Simpson JF, Page DL, Dupont WD. Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. Mod Pathol. 2015;28(5):662.","journal-title":"Mod Pathol"},{"issue":"S4","key":"1287_CR9","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/1097-0142(19800815)46:4+<919::AID-CNCR2820461311>3.0.CO;2-Z","volume":"46","author":"PP Rosen","year":"1980","unstructured":"Rosen PP, Braun DW, Kinne DE. The clinical significance of pre-invasive breast carcinoma. Cancer. 1980;46(S4):919\u201325.","journal-title":"Cancer."},{"issue":"9","key":"1287_CR10","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/cncr.20979","volume":"103","author":"LC Collins","year":"2005","unstructured":"Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy. Cancer. 2005;103(9):1778\u201384.","journal-title":"Cancer."},{"issue":"3","key":"1287_CR11","first-page":"223","volume":"11","author":"V Eusebi","year":"1994","unstructured":"Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol. 1994;11(3):223\u201335.","journal-title":"Semin Diagn Pathol"},{"issue":"9","key":"1287_CR12","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/jnci\/djy220","volume":"111","author":"Marc D Ryser","year":"2019","unstructured":"Ryser MD, Weaver DL, Zhao F, et al. Cancer Outcomes in DCIS Patients Without Locoregional Treatment. J Natl Cancer Inst. 2019;111(9):952\u201360.","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"12","key":"1287_CR13","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/S0959-8049(03)00260-0","volume":"39","author":"MF Yen","year":"2003","unstructured":"Yen MF, Tabar L, Vitak B, Smith RA, Chen HH, Duffy SW. Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer. 2003;39(12):1746\u201354.","journal-title":"Eur J Cancer"},{"key":"1287_CR14","doi-asserted-by":"publisher","first-page":"d7017","DOI":"10.1136\/bmj.d7017","volume":"343","author":"A Seigneurin","year":"2011","unstructured":"Seigneurin A, Fran\u00e7ois O, Labar\u00e8re J, Oudeville P, Monlong J, Colonna M. Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. BMJ. 2011;343:d7017.","journal-title":"BMJ."},{"issue":"1","key":"1287_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/bcr1369","volume":"8","author":"HJ de Koning","year":"2005","unstructured":"de Koning HJ, Draisma G, Fracheboud J, de Bruijn A. Overdiagnosis and overtreatment of breast cancer: microsimulation modelling estimates based on observed screen and clinical data. Breast Cancer Res. 2005;8(1):202.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"1287_CR16","doi-asserted-by":"publisher","first-page":"djv372","DOI":"10.1093\/jnci\/djv372","volume":"108","author":"MD Ryser","year":"2015","unstructured":"Ryser MD, Worni M, Turner EL, Marks JR, Durrett R, Hwang ES. Outcomes of active surveillance for ductal carcinoma in situ: a computational risk analysis. J Natl Cancer Inst. 2015;108(5):djv372.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1287_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/epirev\/mxr009","volume":"33","author":"R De Gelder","year":"2011","unstructured":"De Gelder R, Heijnsdijk EAM, Van Ravesteyn NT, Fracheboud J, Draisma G, De Koning HJ. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev. 2011;33(1):111\u201321.","journal-title":"Epidemiol Rev"},{"issue":"8","key":"1287_CR18","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1038\/bjc.2013.471","volume":"109","author":"KHX Tan","year":"2013","unstructured":"Tan KHX, Simonella L, Wee HL, Roellin A, Lim YW, Lim WY, et al. Quantifying the natural history of breast cancer. Br J Cancer. 2013;109(8):2035.","journal-title":"Br J Cancer"},{"issue":"6","key":"1287_CR19","doi-asserted-by":"publisher","first-page":"R152","DOI":"10.1186\/bcr3365","volume":"14","author":"NB Gunsoy","year":"2012","unstructured":"Gunsoy NB, Garcia-Closas M, Moss SM. Modelling the overdiagnosis of breast cancer due to mammography screening in women aged 40 to 49 in the United Kingdom. Breast Cancer Res. 2012;14(6):R152.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1287_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.clon.2014.09.015","volume":"27","author":"A Francis","year":"2015","unstructured":"Francis A, Fallowfield L, Rea D. The LORIS trial: addressing overtreatment of ductal carcinoma in situ. Clin Oncol. 2015;27(1):6\u20138.","journal-title":"Clin Oncol"},{"issue":"12","key":"1287_CR21","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","volume":"51","author":"LE Elshof","year":"2015","unstructured":"Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ\u2013the LORD study. Eur J Cancer. 2015;51(12):1497\u2013510.","journal-title":"Eur J Cancer"},{"key":"1287_CR22","first-page":"62","volume":"102","author":"LM Youngwirth","year":"2017","unstructured":"Youngwirth LM, Boughey JC, Hwang ES. Surgery versus monitoring and endocrine therapy for low-risk DCIS: the COMET trial. Bull Am Coll Surg. 2017;102:62\u20133.","journal-title":"Bull Am Coll Surg"},{"issue":"1_suppl","key":"1287_CR23","doi-asserted-by":"publisher","first-page":"44S","DOI":"10.1177\/0272989X17741634","volume":"38","author":"Sandra J. Lee","year":"2018","unstructured":"Lee SJ, Li X, Huang H, Zelen M. The Dana-Farber CISNET Model for Breast Cancer Screening Strategies: An Update. Med Decis Making. 2018;38(1_suppl):44S\u201053S.","journal-title":"Medical Decision Making"},{"issue":"36","key":"1287_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/jncimonographs\/lgj011","volume":"2006","author":"S Lee","year":"2006","unstructured":"Lee S, Zelen M. Chapter 11: a stochastic model for predicting the mortality of breast cancer. JNCI Monographs. 2006;2006(36):79\u201386.","journal-title":"JNCI Monographs"},{"key":"1287_CR25","doi-asserted-by":"crossref","unstructured":"van den Broek JJ, van Ravesteyn NT, Heijnsdijk EA, de Koning HJ. Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia. Med Decis Making. 2018;38(1_suppl):54S\u201065S.","DOI":"10.1177\/0272989X17711928"},{"issue":"36","key":"1287_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/jncimonographs\/lgj009","volume":"2006","author":"SYGL Tan","year":"2006","unstructured":"Tan SYGL, Van Oortmarssen GJ, De Koning HJ, Boer R, Habbema JDF. Chapter 9: the MISCAN-Fadia continuous tumor growth model for breast cancer. JNCI Monographs. 2006;2006(36):56\u201365.","journal-title":"JNCI Monographs."},{"issue":"444","key":"1287_CR27","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1080\/01621459.1998.10473788","volume":"93","author":"SJ Lee","year":"1998","unstructured":"Lee SJ, Zelen M. Scheduling periodic examinations for the early detection of disease: applications to breast cancer. JASA. 1998;93(444):1271\u201381.","journal-title":"JASA."},{"issue":"2","key":"1287_CR28","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1541-0420.2007.00893.x","volume":"64","author":"SJ Lee","year":"2008","unstructured":"Lee SJ, Zelen M. Mortality modeling of early detection programs. Biometrics. 2008;64(2):386\u201395.","journal-title":"Biometrics."},{"key":"1287_CR29","unstructured":"Li X, Weedon-Fekjaer H, Lee SJ. Evaluating the natural history of dectal carcinomc in situ breast cancer using Norwegian breast cancer screening program data. Stat Methods Med Res. 2018:In press."},{"issue":"1_suppl","key":"1287_CR30","doi-asserted-by":"publisher","first-page":"126S","DOI":"10.1177\/0272989X17729358","volume":"38","author":"NT van Ravesteyn","year":"2018","unstructured":"van Ravesteyn NT, van den Broek JJ, Li X, Weedon-Fekj\u00e6r H, Schechter CB, Alagoz O, et al. Modeling ductal carcinoma in situ (DCIS): an overview of CISNET model approaches. Med Decis Making. 2018;38(1_suppl):126S\u201339S.","journal-title":"Med Decis Making"},{"key":"1287_CR31","doi-asserted-by":"crossref","unstructured":"Munoz D, Near AM, van Ravesteyn NT, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst. 2014;106(11):dju289.","DOI":"10.1093\/jnci\/dju289"},{"issue":"2","key":"1287_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1001\/jama.2017.19130","volume":"319","author":"SK Plevritis","year":"2018","unstructured":"Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, et al. Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000-2012. JAMA. 2018;319(2):154\u201364.","journal-title":"JAMA."},{"issue":"17","key":"1287_CR33","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1056\/NEJMoa050518","volume":"353","author":"DA Berry","year":"2005","unstructured":"Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784\u201392.","journal-title":"N Engl J Med"},{"issue":"4","key":"1287_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.7326\/M15-1536","volume":"164","author":"JS Mandelblatt","year":"2016","unstructured":"Mandelblatt JS, Stout NK, Schechter CB, Van Den Broek JJ, Miglioretti DL, Krapcho M, et al. Collaborative modeling of the benefits and harms associated with different US breast cancer screening strategies. Ann Intern Med. 2016;164(4):215\u201325.","journal-title":"Ann Intern Med"},{"key":"1287_CR35","unstructured":"Mandelblatt JS, Cronin K, de Koning H, Miglioretti DL, Schechter CS, Stout N. Modeling Report: Collaborative Modeling of U.S. Breast Cancer Screening Strategies. AHRQ Publication No. 14-05201-EF-4. Rockville, MD: U.S. Preventive Services Task Force; 2015."},{"issue":"1","key":"1287_CR36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1148\/radiol.10091881","volume":"256","author":"LE Ichikawa","year":"2010","unstructured":"Ichikawa LE, Barlow WE, Anderson ML, Taplin SH, Geller BM, Brenner RJ. Time trends in radiologists\u2019 interpretive performance at screening mammography from the community-based Breast Cancer Surveillance Consortium, 1996\u20132004. Radiology. 2010;256(1):74\u201382.","journal-title":"Radiology."},{"issue":"1_suppl","key":"1287_CR37","doi-asserted-by":"publisher","first-page":"9S","DOI":"10.1177\/0272989X17700624","volume":"38","author":"JS Mandelblatt","year":"2018","unstructured":"Mandelblatt JS, Near AM, Miglioretti DL, Munoz D, Sprague BL, Trentham-Dietz A, et al. Common model inputs used in CISNET collaborative breast cancer modeling. Med Decis Making. 2018;38(1_suppl):9S\u201323S.","journal-title":"Med Decis Making"},{"issue":"1","key":"1287_CR38","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10549-011-1430-5","volume":"129","author":"EM Ozanne","year":"2011","unstructured":"Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ. Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat. 2011;129(1):165\u201373.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"1287_CR39","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s10552-005-0693-8","volume":"16","author":"KA Cronin","year":"2005","unstructured":"Cronin KA, Yu B, Krapcho M, Miglioretti DL, Fay MP, Izmirlian G, et al. Modeling the dissemination of mammography in the United States. Cancer Causes Control. 2005;16(6):701\u201312.","journal-title":"Cancer Causes Control"},{"issue":"1","key":"1287_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13058-016-0705-5","volume":"18","author":"PA Van Luijt","year":"2016","unstructured":"Van Luijt PA, Heijnsdijk EAM, Fracheboud J, Overbeek LIH, Broeders MJM, Wesseling J, et al. The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening. Breast Cancer Res. 2016;18(1):47.","journal-title":"Breast Cancer Res"},{"issue":"3","key":"1287_CR41","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10549-016-3839-3","volume":"157","author":"G Szalayova","year":"2016","unstructured":"Szalayova G, Ogrodnik A, Spencer B, Wade J, Bunn J, Ambaye A, et al. Human breast cancer biopsies induce eosinophil recruitment and enhance adjacent cancer cell proliferation. Breast Cancer Res Treat. 2016;157(3):461\u201374.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1287_CR42","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10911-018-9415-1","volume":"23","author":"K Doke","year":"2018","unstructured":"Doke K, Butler S, Mitchell MP. Current therapeutic approaches to DCIS. J Mammary Gland Biol Neoplasia. 2018;23(4):279\u201391.","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"1","key":"1287_CR43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S1470-2045(15)00446-5","volume":"17","author":"SW Duffy","year":"2016","unstructured":"Duffy SW, Dibden A, Michalopoulos D, Offman J, Parmar D, Jenkins J, et al. Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study. Lancet Oncol. 2016;17(1):109\u201314.","journal-title":"Lancet Oncol"},{"key":"1287_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.breast.2016.04.013","volume":"28","author":"A Seigneurin","year":"2016","unstructured":"Seigneurin A, Labar\u00e8re J, Fran\u00e7ois O, Exbrayat C, Dupouy M, Filippi M, et al. Overdiagnosis and overtreatment associated with breast cancer mammography screening: a simulation study with calibration to population-based data. Breast. 2016;28:60\u20136.","journal-title":"Breast"},{"issue":"1_suppl","key":"1287_CR45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1258\/jms.2012.012082","volume":"19","author":"D Puliti","year":"2012","unstructured":"Puliti D, Duffy SW, Miccinesi G, De Koning H, Lynge E, Zappa M, et al. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen. 2012;19(1_suppl):42\u201356.","journal-title":"J Med Screen"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-01287-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-020-01287-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-01287-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T19:51:53Z","timestamp":1622058713000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-020-01287-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1287"],"URL":"https:\/\/doi.org\/10.1186\/s13058-020-01287-6","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"21 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}